By Aphios Corp.
A Multiple Sclerosis disease-modifying therapeutic that activates the PPARγ pathway expressing both anti-inflammatory and neuroprotective bioactivities Orally Bioavailable Nanotechnology Formulation APH-1403 is a nanotechnology formulation of CBD designed to increase its oral bioavailability. APH-1403 is manufactured using an environmentally friendly enabling technology platform to nanoencapsulate CBD in biodegradable polymer nanospheres [US Patents]. This nanoformulation enhances the oral bioavailability of this first-in-class compound which bypasses first-round metabolism in the liver, thereby improving its safety and increasing therapeutic efficacy. This green nanotechnology platform has been previously used to nanoencapsulate a similar molecule class without the use of organic solvents [US Patent]. If successful, the introduction of CBD as an orally available biological response modifier will allow earlier and simpler treatment for MS flares, and prevent progression of disability and primary/secondary progressive MS (PPMS/SPMS).
Consisting of an HIV strain, inactivated by three orthogonal methods: a genetic method to attenuate the virus, a physical method called CFI and a chemical method called AT-2 Our therapeutic HIV/AIDS vaccine consists of an inactivated a strain of HIV, inactivated by three orthogonal methods: a genetic method to attenuate the virus, a physical method called CFI and a chemical method called AT-2. These methods inactivate HIV without causing major structural and physical damage to the virion, including gp120. Such a vaccine preparation should induce both humoral and cellular immune responses. We expect the inactivated attenuated virion to behave similarly to live HIV, with the exception of integration and replication. Thus, the inactivated attenuated virion will bind to and be taken up by dendritic cells and macrophages, which will then present antigens to CD4+ and CD8+ T cells for the generation of T cell help and cytotoxic T cells. Previous experiments in chimpanzees showed that good humoral and cellular responses could be induced with an inactivated, whole HIV immunogen. A more recent study showed induction of humoral and cellular responses with virus-like particles. Finally, both humoral and cellular responses were generated after immunization with AT-2 inactivated SIV. Partnering Opportunity We are seeking global partnerships for developing an HIV therapeutic vaccine that could lead to a functional cure for HIV/AIDS patients. Learn more
CATEGORY
We will also provide research-scale units to biotechnology companies, universities and research institutions to complement and improve your research and development activities.
CATEGORY
Taxanes from Yew Aphios produces natural paclitaxel from the needles of the American and Canadian yew (Taxus media, Taxus canadensis), along with cephalomannine and the paclitaxel intermediates 10-DAB and 9-DHAB. All are isolated with SuperFluids™ CXP technology at 98 to 99% purity. Generic Name: 10-deacetylbaccatin III (10-DAB) Catalog Number: APH-93083 Molecular Formula: C 29 H 36 O 10 Molecular Weight: 544.60 Source: Taxus media "hicksii" or Taxus canadensis
CATEGORY
Taxanes from Yew Aphios produces natural paclitaxel from the needles of the American and Canadian yew (Taxus media, Taxus canadensis), along with cephalomannine and the paclitaxel intermediates 10-DAB and 9-DHAB. All are isolated with SuperFluids™ CXP technology at 98 to 99% purity. Generic Name: Cephalomannine Catalog Number: APH-93082 Molecular Formula: C 45 H 53 NO 14 Molecular Weight: 831.91 Source: Taxus media "hicksii" or Taxus canadensis
CATEGORY
